Hematologic Malignancy Clinical Trial
Official title:
Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation
Lung is one of the target organs in chronic graft versus host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Bronchiolitis obliterans syndrome (BOS) after allo-HSCT was a clinical syndrome characterized by persistent airflow restriction which is the result of lung cGVHD. BOS is one of the main causes of late mortality after allo-HSCT, severely restricting the daily activities and respiratory function of patients. It limits the quality of life and increased the non-relapse mortality (NRM) after allo-HSCT. Currently, the first-line treatment for BOS is FAM ( oral fluticasone, azithromycin and montelukast). However, more than 50% of patients develop as steroids resistant (SR)-BOS, and SR-BOS has a poor prognosis and irreversible impaired lung function. Ruxolitinib is an effective drug in the treatment of SR-cGVHD. This is a phase Ⅱ prospective clinical study to explore the efficacy and safety of ruxolitinib as a first-line treatment for newly diagnosed BOS after allo-HSCT.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | January 1, 2025 |
Est. primary completion date | June 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Male or female; 18-65 years old 2. Diagnosis of BOS after allo-HCT defined as the 2014 NIH criteria 3. Life expectancy > 6 months at the time of enrollment 4. At least 4 weeks since initiation of the most recent systemic therapy for cGVHD or BOS 5. The ability to understand and willingness to sign a written consent document Exclusion Criteria: 1. Recurrent malignancy or disease progression requiring anticancer therapy 2. Currently receiving or have previously received ruxolitinib for chronic GVHD therapy 3. Known history of allergy to ruxolitinib or its excipients 4. Hepatic dysfunction: transaminases (ALT, AST) > 5X ULN and/or total bilirubin > 3X ULN 5. Hematologic dysfunction: absolute neutrophil count <1000/µL, platelet cout <30*10E9/L, and/or Hgb < 8 g/dL 6. Renal dysfunction: calculated creatinine clearance < 30 mL/min (Cockcroft-Gault formula) 7. previously received second-line treatment or any drugs in clinical trials for cGVHD |
Country | Name | City | State |
---|---|---|---|
China | The first Affiliated Hospital of Zhejiang University | Hangzhou | Zhejiang |
Lead Sponsor | Collaborator |
---|---|
First Affiliated Hospital of Zhejiang University | First Affiliated Hospital of Wenzhou Medical University, Jinhua Central Hospital, Ningbo No. 1 Hospital, Second Affiliated Hospital, School of Medicine, Zhejiang University, Sir Run Run Shaw Hospital, Taizhou Hospital, The Affiliated People's Hospital of Ningbo University, The First Affiliated Hospital of Zhejiang Chinese Medical University, Union hospital of Fujian Medical University, Xiangya Hospital of Central South University, Zhejiang Provincial People's Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | absolute FEV1 increase | The proportion of participants with a sustained, absolute FEV1 increase by = 10% after 3 months of treatment with ruxolitinib (compared to baseline measure prior to study enrollment) | 3 Months | |
Secondary | treatment failure rate | The proportion of participants who do not experience a sustained, absolute decrease in FEV1 by = 10% after 3 months of treatment with ruxolitinib (compared to baseline measure prior to study enrollment) | 3 Months | |
Secondary | absolute FEV1 increase | The proportion of participants with a sustained, absolute FEV1 increase by = 10% after treatment with ruxolitinib (compared to baseline measure prior to study enrollment) | 6 Months, 9 Months, 12 Months and 24 Months | |
Secondary | Improvements in chronic GVHD organ specific manifestations | mprovements in chronic GVHD organ specific manifestations will be categorized according to the NIH chronic GVHD consensus criteria. | 6 Months, 9 Months, 12 Months and 24 Months | |
Secondary | Overall Survival | The proportion of patients survival at two years after enrollment of ruxolitinib treatment | 2 years | |
Secondary | cGVHD progression-free survival | Participants alive without cGVHD progression are censored at the date of last disease evaluation | 2 years | |
Secondary | The incidence and types of serious adverse events | Adverse events are graded according to Common Terminology Criteria for Adverse Events (CTCAE v4) | From the start of treatment until 30 days after the end of treatment, up to 2 years | |
Secondary | The change of systemic corticosteroid dose over time | The change of systemic corticosteroid dose over time during the treatment of BOS | From the start of treatment until the end of treatment, up to 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Recruiting |
NCT04889937 -
Usability, Adherence and Diagnostic Performance of PointCheck in Pediatric Population
|
||
Not yet recruiting |
NCT05820126 -
Cold Versus Room Temperature Storage of Platelets for Bleeding in Hematologic Malignancy - a Pilot Trial
|
Phase 2 | |
Active, not recruiting |
NCT04509765 -
A Phase II Single-arm Study of Total Body Irradiation With Linac Based VMAT and IGRT
|
N/A | |
Not yet recruiting |
NCT06350994 -
Early Assessment of Cardiac Function After Treatment With CAR-T Cells
|
||
Withdrawn |
NCT04282174 -
CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies
|
Phase 2 | |
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 | |
Withdrawn |
NCT03986086 -
MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 1/Phase 2 | |
Completed |
NCT02512666 -
Non Invasive Optical Imaging of WBC Count
|
N/A | |
Withdrawn |
NCT02207764 -
Reiki as a Complementary Therapy: A Pilot Study
|
N/A | |
Not yet recruiting |
NCT02193399 -
Physiotherapy in Hematopoietic Stem Cell Transplantation
|
N/A | |
Terminated |
NCT01846429 -
Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain
|
Phase 1 | |
Terminated |
NCT01215981 -
Influenza Vaccine Post Allogeneic Transplant
|
N/A | |
Completed |
NCT00333190 -
CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation
|
N/A | |
Withdrawn |
NCT04392128 -
Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE)
|
Phase 2 | |
Recruiting |
NCT06102213 -
Study To Evaluate The Safety And Efficacy of PBCLN-010 In Combination With PBCLN-014 in Participants Receiving Allogeneic Hematopoietic Cell Transplantation
|
Phase 2 | |
Active, not recruiting |
NCT04552288 -
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
|
Phase 2 | |
Completed |
NCT03654404 -
A Proof-of-Concept Trial of a Positive Psychology Intervention for Allogeneic Stem Cell Transplant Patients
|
N/A | |
Recruiting |
NCT05384288 -
Response to Influenza Vaccination in Pediatric Oncology Patients
|
||
Recruiting |
NCT05084027 -
Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCT
|
Phase 2 |